A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms

abstract

  • The combination of erlotinib and bevacizumab was well-tolerated but had limited activity in unselected patients with previously treated MBC. Biomarkers are needed to identify those MBC patients likely to respond to anti-EGFR/HER1 plus anti-VEGF therapy.

publication date

  • December 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2748748

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-0141

PubMed ID

  • 19047117

Additional Document Info

start page

  • 7878

end page

  • 83

volume

  • 14

number

  • 23